Expect rev to touch Rs 300cr by FY11: Jupiter Bioscience

Jupiter Bioscience expects its Swiss acquisition to be completed by December end this year. Venkat Kolavakolanu, CMD, Jupiter Bioscience, in an interview with CNBC-TV18 said that he expects their Swiss arm to start contributing USD 8-10 million in FY11.

The firm is engaged in the production and selling of peptide group products, drug intermediates, specialty and fine chemicals. They export 30% peptides to the US and 70% to Europe.

ALSO READ See latest News about Jupiter Bio See previous management interviews See what other Experts & Brokerages are saying about Jupiter Bio

He expects revenues to touch Rs 300 crore for this fiscal.

Below is a verbatim transcript of his interview with CNBC-TV18’s Ekta Batra and Reema Tendulkar. Watch the accompanying video for more.

Q: Could you tell us about the status of where this Swiss acquisition is currently at and in terms of an addition what would it add to the topline, bottomline and margins which you expect from the Swiss company for FY11-12?

A: The acquisition formalities will be completed before the end of December. The topline that it would add in this financial year would be close to USD 8-10 million into Jupiter Bioscience Ltd.

Q: Since you work on high margins, how would this Swiss company contribute in terms of consolidated margins?

A: For consolidated margins, the real picture will be seen in the next financial year that is in 2011-2012 where many compounds which have been developed by this company there in the last 10-years, will be scaled up India and then the higher scale of business will be taken up.

Q: Do you see your margins under pressure going forward because of this?

A: No. It is not going to happen that way because we are constantly adding value addition to the products that we have been manufacturing. In the coming two-three years either we will be maintaining the same bottomline or there will be an increase because of the value addition.

Q: What are your expectations for revenues for the entire year?

A: Close to Rs 300 crore.